Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Innate Pharma S.A. is a France-based biotechnology company focused on the discovery, development, and clinical advancement of first-in-class immuno-oncology therapeutics. The company operates within the biopharmaceutical and oncology drug development industries, with a scientific emphasis on harnessing the innate immune system—particularly natural killer (NK) cells and myeloid cells—to treat cancer. Innate Pharma’s core value proposition lies in its proprietary expertise in innate immunity, which differentiates it from companies primarily focused on adaptive immune mechanisms such as T-cell–based therapies.
The company was founded in 1999 as a spin-off from academic research conducted at the Centre d’Immunologie de Marseille-Luminy (CIML) and has since evolved into a clinical-stage biopharmaceutical company listed on Euronext Paris and NASDAQ (ticker: IPHA). Over time, Innate Pharma has transitioned from early discovery research to a portfolio that includes both wholly owned clinical candidates and programs developed through strategic partnerships with large pharmaceutical companies, most notably AstraZeneca and Sanofi.
Business Operations
Innate Pharma’s business operations are centered on research and development of immunotherapies, with revenues primarily generated through collaboration agreements, licensing arrangements, milestone payments, and cost-sharing partnerships, rather than commercial product sales. The company organizes its activities around therapeutic platforms targeting NK cell receptors, myeloid checkpoints, and antibody-based immunotherapies, which support multiple oncology indications including solid tumors and hematologic malignancies.
Key operating programs include monalizumab, lacutamab, and SAR’514, as well as earlier-stage research assets. Innate Pharma maintains full control of its internal R&D capabilities, including antibody engineering and translational research, while leveraging partnerships for late-stage clinical development and potential commercialization. The company operates primarily through its wholly owned subsidiary Innate Pharma US, Inc., which supports clinical development and investor relations activities in the United States.
Strategic Position & Investments
Innate Pharma’s strategic direction is focused on advancing differentiated immuno-oncology assets through clinical proof of concept while selectively partnering programs that require large-scale development resources. A cornerstone of this strategy is its long-term collaboration with AstraZeneca, which includes the co-development of monalizumab and additional NK cell–based antibody programs. The company also maintains a research collaboration with Sanofi focused on antibody discovery and preclinical development.
The company continues to invest in next-generation antibody formats, including ANKET® (Antibody-based NK cell Engagers for Tumor targeting) technology, which represents a key emerging platform within its pipeline. Capital allocation is primarily directed toward internal R&D, clinical trials, and maintaining scientific capabilities, rather than acquisitions of external companies. No material acquisitions have been publicly disclosed in recent reporting periods.
Geographic Footprint
Innate Pharma is headquartered in Marseille, France, where it conducts the majority of its research and development activities. The company’s primary operational presence is concentrated in Europe, with expanding clinical and corporate activities in North America, particularly the United States. Its U.S. subsidiary facilitates engagement with regulators, clinical investigators, and capital markets.
Through multinational clinical trials and global pharmaceutical partnerships, Innate Pharma has operational and investment exposure across Europe, North America, and selected sites in Asia-Pacific, depending on study design. While the company does not maintain large-scale commercial infrastructure, its programs are designed for global development and potential worldwide commercialization through partners.
Leadership & Governance
Innate Pharma is led by an executive team with experience in biotechnology, immunology, and pharmaceutical development, supported by a supervisory board structure consistent with French public company governance standards. Leadership emphasizes scientific rigor, disciplined capital management, and strategic collaboration with larger industry partners to maximize asset value.
Key executives include:
- Hervé Brailly – Co-founder and Chairman of the Executive Board
- Jonathan Dickinson – Chief Executive Officer
- François Romagné – Chief Scientific Officer
- Éric Vivier – Co-founder and President of the Scientific Advisory Board
- Gilles Lasserre – Chief Financial Officer
The leadership team’s strategic vision centers on establishing Innate Pharma as a leading innovator in innate immunity while balancing independent development with value-creating partnerships.